Rapid and dramatic responses to dabrafenib and trametinib in BRAF V600E‐mutated lung adenocarcinoma

V‐raf murine sarcoma viral oncogene homologue B1 (BRAF) is a proto‐oncogene that regulates cell proliferation and survival. BRAF V600E‐mutated lung cancer has aggressive characteristics and is resistant to chemotherapies. Combination of BRAF‐specific inhibitor dabrafenib and mitogen‐activated protei...

Descripción completa

Detalles Bibliográficos
Autores principales: Ota, Takayo, Okabayashi, Aya, Fukuoka, Masahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8403980/
https://www.ncbi.nlm.nih.gov/pubmed/34484797
http://dx.doi.org/10.1002/rcr2.841
_version_ 1783746079988121600
author Ota, Takayo
Okabayashi, Aya
Fukuoka, Masahiro
author_facet Ota, Takayo
Okabayashi, Aya
Fukuoka, Masahiro
author_sort Ota, Takayo
collection PubMed
description V‐raf murine sarcoma viral oncogene homologue B1 (BRAF) is a proto‐oncogene that regulates cell proliferation and survival. BRAF V600E‐mutated lung cancer has aggressive characteristics and is resistant to chemotherapies. Combination of BRAF‐specific inhibitor dabrafenib and mitogen‐activated protein kinase kinase (MEK) inhibitor trametinib is the standard treatment for BRAF V600E‐mutated lung cancer. We report a case of BRAF V600E‐mutated lung adenocarcinoma, which presented with respiratory distress due to deterioration of advanced cancer. The tumour responded rapidly and significantly to BRAF/MEK inhibitors, and the patient's symptoms improved within 2 weeks. BRAF/MEK inhibitors are effective treatment in BRAF‐mutated lung cancer even under critical conditions.
format Online
Article
Text
id pubmed-8403980
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley & Sons, Ltd
record_format MEDLINE/PubMed
spelling pubmed-84039802021-09-03 Rapid and dramatic responses to dabrafenib and trametinib in BRAF V600E‐mutated lung adenocarcinoma Ota, Takayo Okabayashi, Aya Fukuoka, Masahiro Respirol Case Rep Case Reports V‐raf murine sarcoma viral oncogene homologue B1 (BRAF) is a proto‐oncogene that regulates cell proliferation and survival. BRAF V600E‐mutated lung cancer has aggressive characteristics and is resistant to chemotherapies. Combination of BRAF‐specific inhibitor dabrafenib and mitogen‐activated protein kinase kinase (MEK) inhibitor trametinib is the standard treatment for BRAF V600E‐mutated lung cancer. We report a case of BRAF V600E‐mutated lung adenocarcinoma, which presented with respiratory distress due to deterioration of advanced cancer. The tumour responded rapidly and significantly to BRAF/MEK inhibitors, and the patient's symptoms improved within 2 weeks. BRAF/MEK inhibitors are effective treatment in BRAF‐mutated lung cancer even under critical conditions. John Wiley & Sons, Ltd 2021-08-30 /pmc/articles/PMC8403980/ /pubmed/34484797 http://dx.doi.org/10.1002/rcr2.841 Text en © 2021 The Authors. Respirology Case Reports published by John Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Ota, Takayo
Okabayashi, Aya
Fukuoka, Masahiro
Rapid and dramatic responses to dabrafenib and trametinib in BRAF V600E‐mutated lung adenocarcinoma
title Rapid and dramatic responses to dabrafenib and trametinib in BRAF V600E‐mutated lung adenocarcinoma
title_full Rapid and dramatic responses to dabrafenib and trametinib in BRAF V600E‐mutated lung adenocarcinoma
title_fullStr Rapid and dramatic responses to dabrafenib and trametinib in BRAF V600E‐mutated lung adenocarcinoma
title_full_unstemmed Rapid and dramatic responses to dabrafenib and trametinib in BRAF V600E‐mutated lung adenocarcinoma
title_short Rapid and dramatic responses to dabrafenib and trametinib in BRAF V600E‐mutated lung adenocarcinoma
title_sort rapid and dramatic responses to dabrafenib and trametinib in braf v600e‐mutated lung adenocarcinoma
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8403980/
https://www.ncbi.nlm.nih.gov/pubmed/34484797
http://dx.doi.org/10.1002/rcr2.841
work_keys_str_mv AT otatakayo rapidanddramaticresponsestodabrafenibandtrametinibinbrafv600emutatedlungadenocarcinoma
AT okabayashiaya rapidanddramaticresponsestodabrafenibandtrametinibinbrafv600emutatedlungadenocarcinoma
AT fukuokamasahiro rapidanddramaticresponsestodabrafenibandtrametinibinbrafv600emutatedlungadenocarcinoma

Ejemplares similares